But previous investigations have pointed to the potential value of intravenous immunoglobulin (IVIG) therapy as part of a multifaceted approach. And two recent articles seem to further support the benefit for some long COVID sufferers.
“Long-term high-dose immunoglobulin successfully treats long COVID patients with pulmonary, neurologic, and cardiologic symptoms,” published just this month, employed a very small sample but found that all subjects “had a significant to remarkable clinical benefit” at a dose of .5 gram/kg administered every other week.
Findings in “Intravenous immunoglobulins in the treatment of post-COVID: A case–control study,” published in late 2022, suggest that IVIG was a viable candidate approach for post-COVID issues. While also a relatively small-sized study, the research does point to further evaluating the efficacy of IVIG in future randomized controlled trials.
IVIG contains a broad spectrum of anti-idiotypic antibodies, which neutralize the deleterious autoimmune antibodies. Molecular mimicry of spike to the body and brain drives high levels of a broad array of autoantibodies. Long COVID/spikopathy can drive long-standing immune dysfunction, which it is posited that IVIG subsequently can help.
I now have three cases in treatment with vaccine-acquired immune deficiency syndrome (VAIDS) or severe immune dysfunction, post vaccine. In these patients, IVIG can upregulate autophagy, reduce the inflammasome driving microglial cell activation,
and so much more.
I review the benefits of IVIG in this recent blog that also examines another recent IVIG study in an animal model: https://www.suzannegazdamd.com/blog---long-covid/the-downfall-of-the-brain-in-long-covid-and-what-we-can-do-to-help
The treatment of long COVID and spike-induced disease post vaccine is very complicated; it is not a “one solution” regimen, but I do believe that IVIG can be helpful to some patients and should be considered in a comprehensive protocol.
In hope and healing,
Dr. Suzanne Gazda
Thompson JS, Thornton AC, Ainger T and Garvy BA (2023) Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Front. Immunol. 13:1033651. doi: 10.3389/fimmu.2022.1033651
Hogeweg, M, Doevelaar, A, Rieckmann, S, Seibert, F, Scholten, D, Segelmacher, M, et al. Intravenous immunoglobulins in the treatment of post-COVID: A case–control study. J Intern Med. 2022; 00: 00– 00.